Answers are grounded in this paper and cite their sources.
Ipilimumab plus nivolumab (IPI-NIVO) is a standard first line regimen for intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), but real-world data in Chinese patients are scarce. We report, to our knowledge, the first and largest Chinese cohort receiving first-line IPI-NIVO. In this single-centre retrospective study of 60 consecutive Chinese patients with mRCC, best response was assessed per RECIST 1.1. Progression-free (PFS) and overall survival (OS) were estimated by Kaplan–Meier analysis; a pre-specified six-month landmark analysis with Cox adjustment was undertaken to evaluate the association between early disease control and survival. Median age was 63 years (IQR 57–67); 33% had poor-risk IMDC. The objective response rate was 20.0% (95% CI 10.8–32.3) in the intention-to-treat population and 22.6% (95% CI 12.3–36.2) among evaluable patients, with no complete responses observed; the disease control rate was 50.0%. Median PFS and OS were 10.7 (95% CI 4.1–28.2) and 19.6 (95% CI 12.7–34.1) months; 5-year OS was 19.5%. Disease control at the 6-month landmark was strongly associated with OS (adjusted hazard ratio 0.16; 95% CI 0.05–0.49; p = 0.0014). Any-grade and grade ≥ 3 immune-related adverse events occurred in 58.3% and 5.0%, respectively. First-line IPI-NIVO achieved PFS comparable to CheckMate 214 and other non-Chinese Asian series in this cohort. OS was lower than in the randomised trial, likely reflecting limited access to subsequent-line therapies, as only 47% of first-line failures received any second-line treatment. Durable disease control, rather than objective response, characterised long-term survival.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: